Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.
Pamela S DouglasTriin UmblejaGerald S BloomfieldCarl J FichtenbaumMarkella V ZanniEdgar T OvertonKathleen V FitchEmma M KileelJudith A AbergJudith CurrierCraig A SponsellerKathleen MelbourneAnchalee AvihingsanonFlavio BustorffVicente EstradaKiat RuxrungthamMaria SaumoyAnn Marie NavarUdo HoffmannHeather J RibaudoSteven GrinspoonPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Poor CV health by LS7 was common among REPRIEVE participants, regardless of PCE. This suggests a critical and independent role for lifestyle interventions in conjunction with conventional treatment to improve CV outcomes in PWH. Clinical Trials Registration: NCT02344290. AIDS Clinical Trials Group study number: A5332.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- clinical trial
- hiv infected
- hepatitis c virus
- hiv positive
- healthcare
- public health
- hiv aids
- phase ii
- phase iii
- health information
- mental health
- physical activity
- study protocol
- metabolic syndrome
- cardiovascular disease
- open label
- randomized controlled trial
- double blind
- health promotion
- type diabetes
- social media
- human health
- hiv testing
- men who have sex with men
- south africa
- combination therapy